Educational resources

This section includes resources developed by Guidelines, including algorithms, medicines appraisal cards, supplements, and videos. Items may contain pharmaceutical promotional information.

20220124 On demand HRT webinar SPIN block_V.1

Hormone replacement therapy (HRT): Overview and focus on progestogens

Commissioned by Viatris

This promotional webinar has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0346 March 2022

Webinar icon

Half-day virtual event focusing on practical approaches to management of gastrointestinal disorders and iron deficiency

Commissioned by Norgine Pharmaceuticals Limited

Information intended for UK healthcare professionals only. This promotional event has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines.
UK-COR-NP-2100043
Date of preparation: July 2021

20220124 HRT video SPIN block_V.1

Hormone replacement therapy (HRT): what is the role of the progestogen?

Commissioned by Viatris

This promotional video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0362 March 2022

On-demand index image2

The impact of DOACs on stroke in patients with NVAF: practical considerations for those with comorbidities

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.   The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100966 | Date of preparation: January 2022

Dickman index image

Targeting the cause of opioid-induced constipation with PAMORAs

Commissioned by Sandoz Limited

This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141580 | Date of preparation: September 2021

Acne videos Index image

Acne vulgaris: management

Commissioned by Galderma UK Ltd

These videos have been funded by Galderma UK Ltd and developed in conjunction with Guidelines. The content on this page is intended for UK healthcare professionals only.
View Epiduo 0.1%/2.5% (adapalene and benzoyl peroxide) gel prescribing information
View Epiduo 0.3%/2.5% (adapalene and benzoyl peroxide) gel prescribing information
UKI-NBD-2100060 | January 2022

FINAL video image

Management of obesity in primary care: a Guidelines algorithm

Funded by Novo Nordisk Limited

Information intended for UK healthcare professionals only. These videos have been funded through an arm’s-length sponsorship by Novo Nordisk Limited. Guidelines approached Novo Nordisk Limited to fund the production of these videos. 
Date of preparation: December 2021

Pali Hungin index image

Diagnosis and initial management of opioid-induced constipation

Commissioned by Sandoz Limited

This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141579 | Date of preparation: September 2021

20-SZ-4809 index image_v1

Opioid-induced constipation: optimal management and the role of PAMORA drugs

Commissioned by Sandoz Limited

These promotional videos have been funded by Sandoz Ltd and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141578 | Date of preparation: September 2021

index

Management of common eye conditions: blepharitis

Funded by Allergan plc

Fiona Chiu (Moorfields Eye Hospital NHS Foundation Trust) explains the symptoms and management of blepharitis.

index 2

Management of common eye conditions: conjunctivitis

Funded by Allergan plc

Sarah Thomas (Moorfields Eye Hospital NHS Foundation Trust) describes the causes, symptoms, and treatment of conjunctivitis.

dry eye index image

Management of common eye conditions: dry eye

Funded by Allergan plc

Fiona Chiu (Moorfields Eye Hospital NHS Foundation Trust) covers the presentation, causes, and treatment of dry eye.

Final version_Sixmo SMC card

Sixmo®▼ (buprenorphine) 74.2mg implant SMC2372

Commissioned and funded by Accord Healthcare Limited

The production of this Guidelines card has been commissioned by Accord Healthcare Limited.
View adverse event reporting and prescribing information
UK-03735 April 2022

Klisyri (tirbanibulin) SMC card - digital

Tirbanibulin 10mg/g ointment (Klisyri®▼) SMC2395

Commissioned by Almirall Ltd

The production of this Guidelines card has been commissioned by Almirall Ltd.
View prescribing and adverse event reporting information
IE-KLI-2100016 December 2021

Daiichi Sankyo logo

Bempedoic acid (Nilemdo®▼) and Bempedoic acid / ezetimibe (Nustendi®▼) SMC card

Commissioned and funded by Daiichi Sankyo

The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK. This content is for healthcare professionals only.
View Bempedoic acid (Nilemdo®) & Bempedoic acid and ezetimibe (Nustendi®) prescribing and adverse event reporting information
BEM/21/0777 December 2021

20201002 Rizmoic TA card V5 image

NICE Technology Appraisal 651: Naldemedine ▼ for treating opioid‑induced constipation

Commissioned by Sandoz Limited

The production and printing of this Guidelines summary card has been commissioned by Sandoz Ltd. Information intended for UK healthcare professionals only.
View prescribing information

UK/P/RZM/20-0016c October 2020

DuoResp Spiromax (budesonide:formoterol) prescribing summary card

DuoResp® Spiromax® (budesonide/formoterol)

Commissioned by Teva UK Limited

This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.

Click here for prescribing information and adverse event reporting

DUOR-GB-00117
Date of preparation: March 2022

Soolantra prescribing summary card_Index image

Soolantra® (ivermectin) 10 mg/g cream

Commissioned by Galderma UK Ltd

This prescribing summary card was developed from content provided by Galderma UK Ltd. Information intended for UK healthcare professionals only. 
View Soolantra® (ivermectin) 10 mg/g cream prescribing and adverse event reporting information.
UKI-SOC-2100031 September 2021

Guidelines supplements are written by experts and typically discuss a piece of national guidance, pulling out key learning points for GPs.

Animation index image

Changes to the NICE atrial fibrillation (AF) guideline and anticoagulation treatment options—what do they mean to you?

Commissioned by Bayer plc

This promotional animation has been commissioned by Bayer plc and developed in partnership with Guidelines
View Xarelto (rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-2154 December 2021

RICOCHET study supplement

A national audit of pancreatic enzyme replacement therapy (PERT) prescribing in patients with pancreatic cancer: The RICOCHET study

Commissioned by Viatris

This supplement has been commissioned and funded by Viatris and developed in partnership with Guidelines
NON-2021-4065 February 2022

Final version_Opioid supplement

Appropriate use of opioids for chronic pain in primary care

Commissioned by Grünenthal Ltd

This promotional supplement has been commissioned and funded by Grünenthal and developed in partnership with Guidelines. Information intended for healthcare professionals only.
View PALEXIA® SR tablets (tapentadol hydrochloride) prescribing and adverse event reporting information
M-PLX-UK-10-21-0036 October 2021

Final version - HE algorithm

Management of hepatic encephalopathy in primary care

Commissioned by Norgine Pharmaceuticals Limited

This management algorithm has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
View TARGAXAN® (rifaximin-α) prescribing and adverse event reporting information
UK-HEP-XIF-2100040  October 2021

A nurse consulting with a woman in WPG Yellow

Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes

By Working party–Down Beba Davies Diggle Goel

This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.

Viatris HRT algorithm supplement_Index image

Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone

Commissioned by Viatris

This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021

Stack of fruits, white weight scale and tailor meter on wooden board_AS

Managing obesity in primary care

By Development Group—Tahrani Parretti O’Kane Chowhan Ratcliffe and Le Brocq

This management algorithm was developed by a multidisciplinary expert panel: Tahrani et al with the support of an educational grant from Novo Nordisk Limited. Information intended for UK healthcare professionals.

AdobeStock_212764468

Identifying and managing allergic rhinitis in the asthma population

By Development Group—Scadding Holmes Ryan and Williams

This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.

X-ray (female pelvis) 397x302

Osteoporotic fracture guideline

By Working party—Cooper Javaid Elliott Stephens Tanna

This guideline was developed by a multidisciplinary expert panel: Cooper C et al with the support of an educational grant from UCB Pharma Ltd.

An inhaler in WPG Yellow

Inhaler choice guideline

By Development group—Usmani Capstick Saleem Scullion

This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.

Preconception advice

Women of child-bearing age with inflammatory rheumatic diseases guideline

By Working party—Giles Allen Nelson-Piercy Tower Warburton Gordon

This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.

Doctor talking to male patient in office

Guideline for the managed introduction of biosimilar basal insulin

By Working party—Down Beba Brown Diggle Goel Milne

This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.

Nurse giving patient water use glass syringe to irrigate nasogastric tube in hospital

Medication management of patients with enteral feeding tubes

By Working party—Wright Griffith Merriman Smithard Smyth Welsh

This guideline was developed by a multidisciplinary expert panel: Wright D et al with the support of a grant from Rosemont Pharmaceuticals Ltd.

Calculating renal function animation

Calculating renal function in patients with atrial fibrillation

Developed and funded by the Bristol Myers Squibb/Pfizer Alliance

This animation has been developed and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals.

432-GB-2100230  June 2021

Management of opioid-induced constipation

The role of peripherally acting µ-opioid receptor antagonists (PAMORAs) in the management of opioid-induced constipation (OIC)

Commissioned by Sandoz Limited

This educational reference document has been initiated, commissioned, and developed by Sandoz Ltd. Information intended for UK healthcare professionals only. 
View prescribing information

UK/MKT/RZM/20-0029f October 2020

Guidelines supplements are written by experts and typically discuss a piece of national guidance, pulling out key learning points for GPs.

Index image

Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care

Commissioned by Amgen Ltd

This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only. 
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2416 March 2022

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2415 January 2022

Index image

Management of venous thromboembolism in primary care

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100953 | February 2022